US 12344656
Genetically engineered T cells having improved persistence in culture
granted A61KA61K2239/31A61K2239/38
Quick answer
US patent 12344656 (Genetically engineered T cells having improved persistence in culture) held by CRISPR THERAPEUTICS AG expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K31/7105